PharmacoEconomics

Letter From the Commissioner's Office at the US FDA
pp. 1-2(2)
Author: Vernon, John A.

Rates and Probabilities in Economic Modelling: Transformation, Translation and Appropriate Application
pp. 3-6(4)
Authors: Fleurence, Rachael L.; Hollenbeak, Christopher S.

Reducing the Societal Burden of Depression: A Review of Economic Costs, Quality of Care and Effects of Treatment
pp. 7-24(18)
Authors: Donohue, Julie M.; Harold Alan Pincus,

Cost Effectiveness of a Pharmacy-Based Coaching Programme to Improve Adherence to Antidepressants
pp. 25-37(13)
Authors: Bosmans, Judith E.; Brook, Oscar H.; van Hout, Hein P.J.; de Bruijne, Martine C.; Nieuwenhuyse, Hugo; Bouter, Lex M.; Stalman, Wim A.B.; van Tulder, Maurits W.

A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK
pp. 39-54(16)
Authors: Tilden, Dominic P.; Mariz, Segundo; O'Bryan-Tear, Gillies; Bottomley, Julia; Diamantopoulos, Alexander

Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis
pp. 55-71(17)
Authors: Nuijten, Mark J.C.; Wittenberg, Wolfgang; Lebmeier, Maximilian

Time Preferences for Health in Northern Tanzania: An Empirical Analysis of Alternative Discounting Models
pp. 73-88(16)
Authors: Robberstad, Bjarne; Cairns, John